количество зарегистрированных пользователей: 69019

Rumedo Медицинский образовательный портал

МЕДИЦИНСКИЙ ОБРАЗОВАТЕЛЬНЫЙ ПОРТАЛ

Академия инновационного образования

БИБЛИОТЕКА

По категориям

По специальностям

  • Зарубежные материалы

    Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

    Дата публикации 22.10.2020
    Автор: Benjamin M. Scirica, M.D., M.P.H., Deepak L. Bhatt, M.D., M.P.H., Eugene Braunwald, M.D., P. Gabriel Steg, M.D., Jaime Davidson, M.D., Boaz Hirshberg, M.D., Peter Ohman, M.D., Robert Frederich, M.D., Ph.D., Stephen D. Wiviott, M.D., Elaine B. Hoffman, Ph.D., Matthew A. Cavender, M.D., M.P.H., Jacob A. Udell, M.D., M.P.H., Nihar R. Desai, M.D., M.P.H., Ofri Mosenzon, M.D., Darren K. McGuire, M.D., Kausik K. Ray, M.D., Lawrence A. Leiter, M.D., and Itamar Raz, M.D., for the SAVOR-TIMI 53 Steering Committee and Investigators

    The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear.

    Подробнее

    885

  • Статьи

    Алгоритмы специализированной медицинской помощи больным сахарным диабетом (9-й выпуск)

    Дата публикации 22.10.2020
    Под редакцией: И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова

    Данное издание содержит восьмой актуализированный выпуск клинических рекомендаций по стандартизации и оптимизации оказания медицинской помощи больным сахарным диабетом во всех регионах России на основе доказательной медицины.

    Подробнее

    1122

  • Зарубежные материалы

    Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy

    Дата публикации 22.10.2020
    Автор: Steven E. Kahn, M.B., Ch.B., Steven M. Haffner, M.D., Mark A. Heise, Ph.D., William H. Herman, M.D., M.P.H., Rury R. Holman, F.R.C.P., Nigel P. Jones, M.A., Barbara G. Kravitz, M.S., John M. Lachin, Sc.D., M. Colleen O’Neill, B.Sc., Bernard Zinman, M.D., F.R.C.P.C., and Giancarlo Viberti, M.D., F.R.C.P., for the ADOPT Study Group *

    The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known.

    Подробнее

    784

  • Зарубежные материалы

    Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

    Дата публикации 22.10.2020
    Автор: S.D. Wiviott, I. Raz, M.P. Bonaca, O. Mosenzon, E.T. Kato, A. Cahn, M.G. Silverman, T.A. Zelniker, J.F. Kuder, S.A. Murphy, D.L. Bhatt, L.A. Leiter, D.K. McGuire, J.P.H. Wilding, C.T. Ruff, I.A.M. Gause‑Nilsson, M. Fredriksson, P.A. Johansson, A.-M. Langkilde, and M.S. Sabatine, for the DECLARE–TIMI 58 Investigators

    The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium – glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined.

    Подробнее

    719

  • Зарубежные материалы

    Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial

    Дата публикации 22.10.2020
    Автор: Richard I. G. Holt, Rebecca Gossage-Worrall, Daniel Hind, Michael J. Bradburn, Paul McCrone, Tiyi Morris, Charlotte Edwardson, Katharine Barnard, Marian E. Carey, Melanie J. Davies, Chris M. Dickens, Yvonne Doherty, Angela Etherington, Paul French, Fiona Gaughran, Kathryn E. Greenwood, Sridevi Kalidindi, Kamlesh Khunti, Richard Laugharne, John Pendlebury, Shanaya Rathod, David Saxon, David Shiers, Najma Siddiqi, Elizabeth A. Swaby, Glenn Waller and Stephen Wright on behalf of the STEPWISE Research Group*

    People with schizophrenia die 10–20 years earlier than the general population, with approximately 75% of deaths resulting from physical illness.1 The twofold increased prevalence of overweight and obesity contributes to this excess mortality.2 Some, but not all, studies suggest that dietary

    Подробнее

    668

  • Статьи

    Алгоритмы специализированной медицинской помощи больным сахарным диабетом (8-й выпуск)

    Дата публикации 22.10.2020
    Под редакцией: И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова

    Данное издание содержит девятый актуализированный выпуск (дополненный) клинических рекомендаций по стандартизации и оптимизации оказания медицинской помощи больным сахарным диабетом во всех регионах России на основе доказательной медицины.

    Подробнее

    952

  • Зарубежные материалы

    Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?

    Дата публикации 22.10.2020
    Автор: Iciar Martín-Timón, Cristina Sevillano-Collantes, Amparo Segura-Galindo, Francisco Javier del Cañizo-Gómez

    Diabetes mellitus is a chronic condition that occurs when the body cannot produce enough or effectively use of insulin. Compared with individuals without diabetes, patients with type 2 diabetes mellitus have a considerably higher risk of cardiovascular morbidity and mortality, and are disproportionately affected by cardiovascular disease.

    Подробнее

    919

  • Зарубежные материалы

    Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (The new england journal of medicine)

    Дата публикации 22.10.2020
    Автор: Steven P. Marso, M.D., Gilbert H. Daniels, M.D., Kirstine Brown-Frandsen, M.D., Peter Kristensen, M.D., E.M.B.A., Johannes F.E. Mann, M.D., Michael A. Nauck, M.D., Steven E. Nissen, M.D., Stuart Pocock, Ph.D., Neil R. Poulter, F.Med.Sci., Lasse S. Ravn, M.D., Ph.D., William M. Steinberg, M.D., Mette Stockner, M.D., Bernard Zinman, M.D., Richard M. Bergenstal, M.D., and John B. Buse, M.D., Ph.D., for the LEADER Steering Committee on behalf of the LEADER Trial Investigators

    The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown.

    Подробнее

    690

  • Зарубежные материалы

    Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

    Дата публикации 22.10.2020
    Автор: Rury R. Holman, F.Med.Sci., M. Angelyn Bethel, M.D., Robert J. Mentz, M.D., Vivian P. Thompson, M.P.H., Yuliya Lokhnygina, Ph.D., John B. Buse, M.D., Ph.D., Juliana C. Chan, M.D., Jasmine Choi, M.S., Stephanie M. Gustavson, Ph.D., Nayyar Iqbal, M.D., Aldo P. Maggioni, M.D., Steven P. Marso, M.D., Peter Öhman, M.D., Ph.D., Neha J. Pagidipati, M.D., M.P.H., Neil Poulter, F.Med.Sci., Ambady Ramachandran, M.D., Bernard Zinman, M.D., and Adrian F. Hernandez, M.D., M.H.S., for the EXSCEL Study Group*

    The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown.

    Подробнее

    679

  • Зарубежные материалы

    Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

    Дата публикации 22.10.2020
    Автор: William B. White, M.D., Christopher P. Cannon, M.D., Simon R. Heller, M.D., Steven E. Nissen, M.D., Richard M. Bergenstal, M.D., George L. Bakris, M.D., Alfonso T. Perez, M.D., Penny R. Fleck, M.B.A., Cyrus R. Mehta, Ph.D., Stuart Kupfer, M.D., Craig Wilson, Ph.D., William C. Cushman, M.D., and Faiez Zannad, M.D., Ph.D., for the EXAMINE Investigators

    To assess potentially elevated cardiovascular risk related to new antihyperglycemic drugs in patients with type 2 diabetes, regulatory agencies require a comprehensive evaluation of the cardiovascular safety profile of new antidiabetic therapies. We assessed cardiovascular outcomes with alogliptin, a new inhibitor of dipeptidyl peptidase 4 (DPP-4), as compared with placebo in patients with type 2 ...

    Подробнее

    1017

  • Зарубежные материалы

    Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus

    Дата публикации 22.10.2020
    Автор: John B. Buse, MD, PhD, Co-chair; Henry N. Ginsberg, MD, FAHA, Co-chair; George L. Bakris, MD, FAHA; Nathaniel G. Clark, MD, MS, RD; Fernando Costa, MD, FAHA; Robert Eckel, MD, FAHA; Vivian Fonseca, MD; Hertzel C. Gerstein, MD, MSc, FRCPC; Scott Grundy, MD, FAHA; Richard W. Nesto, MD, FAHA; Michael P. Pignone, MD, MPH; Jorge Plutzky, MD; Daniel Porte, MD; Rita Redberg, MD, FAHA; Kimberly F. Stitzel, MS, RD; Neil J. Stone, MD, FAHA

    Abstract—The American Heart Association (AHA) and the American Diabetes Association (ADA) have each published guidelines for cardiovascular disease prevention: The ADA has issued separate recommendations for each of the cardiovascular risk factors in patients with diabetes, and the AHA has shaped primary and secondary guidelines that extend to patients with diabetes. This statement will attempt to ...

    Подробнее

    834

  • Зарубежные материалы

    Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

    Дата публикации 22.10.2020
    Автор: Eri T. Kato, MD, MPH, PhD et al

    In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the composite end point of cardiovascular death/hospitalization for heart failure (HHF) in a broad population of patients with type 2 diabetes mellitus. However, the impact of baseline left ventricular ejection fraction (EF) ...

    Подробнее

    846

  • Зарубежные материалы

    Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and theEuropeanAssociation for the Study of Diabetes (EASD)

    Дата публикации 22.10.2020
    Автор: Melanie J. Davies,1,2 David A. D’Alessio,3 Judith Fradkin,4 Walter N. Kernan,5 Chantal Mathieu,6 Geltrude Mingrone,7,8 Peter Rossing,9,10 Apostolos Tsapas,11 Deborah J. Wexler,12,13 and John B. Buse14

    The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education ...

    Подробнее

    779

  • Зарубежные материалы

    Obesity and Diabetic Kidney Disease

    Дата публикации 22.10.2020
    Автор: Christine Maric-Bilkan, PhD. Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS, USA

    The prevalence of obesity (body mass index, BMI ≥ 30 kg/m2) has risen to epidemic proportions and continues to be a major health problem worldwide 1–3. The high prevalence of obesity is closely linked to the increased incidence of a number of chronic diseases, including type 2 diabetes, hypertension and cardiovascular disease 2, 4–8.

    Подробнее

    1100

  • Зарубежные материалы

    Eligibility Varies Among the 4 Sodium-Glucose Cotransporter-2 Inhibitor Cardiovascular Outcomes Trials: Implications for the General Type 2 Diabetes US Population

    Дата публикации 22.10.2020
    Автор: Eric T. Wittbrodt, PharmD, MPH; James M. Eudicone, MS, MBA; Kelly F. Bell, PharmD, MSPhr; Devin M. Enhoffer, PharmD; Keith Latham, PharmD; and Jennifer B. Green, MD

    In 2015, more than 23 million adults in the United States had a diagnosis of diabetes, with an estimated 95% of cases being type 2 diabetes (T2D). Patients with T2D are at increased risk of cardiovascular disease (CVD),2 and therefore, improvement of cardiovascular (CV) outcomes is a goal of diabetes management.3,4 Good glycemic control in T2D has been associated with a reduced risk of microvascul ...

    Подробнее

    794